Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study - Concepedia

Concepedia

Publication | Closed Access

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

414

Citations

22

References

2016

Year

Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, Peter Kufer, Max S. Topp, Hermann Einsele, Richard Noppeney, Andréas Mackensen, Kathrin Rupertus, Lothar Kanz,

Journal of Clinical Oncology

Abstract

In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m(2)/day. Single-agent blinatumomab showed antilymphoma activity.

References

	Year	Citations

Page 1